Record-High Revenue Driven by Solid Fundamentals; Operating Profit Ranks Among Industry Leaders
R&D Investment Totaled USD 170 Million (KRW 229.0 Billion), Representing 14.8% of Revenue and Reinforcing the Company’s Commitment to Long-Term Value Creation
Operations Fully Normalized, Supported by Resilient Revenue, R&D, Exports, and Organizational Stability
(February 5, 2026) Hanmi delivered the strongest results in its corporate history last year, posting revenue of USD 1.15 billion (KRW 1.5475 trillion) and operating profit of USD 191 million (KRW 257.8 billion). The performance is particularly noteworthy as the Company, following the resolution of a management dispute, swiftly stabilized operations under a professional management team led by CEO Jae-hyun Park, extending its streak of consecutive record highs in 2023 and 2024.
Last year’s results set a new record, surpassing the revenue and operating profit achieved in 2015, when the Company secured Korea’s largest new drug licensing agreement. The achievement is widely seen as evidence that Hanmi Pharmaceutical has moved beyond mere top-line expansion, establishing itself―on the strength of solid fundamentals―as a company where best-in-class, sustainable profit generation and continued R&D reinvestment form a virtuous cycle.
Jae-hyun Park, CEO of Hanmi Pharmaceutical, said, “Through close, organic collaboration across our business divisions―including domestic operations, overseas exports, new product launches, and accelerated R&D innovation―we have further strengthened a sustainable growth system,” adding, “Building on last year’s achievements, we will continue to focus our capabilities on identifying future growth engines and maximizing strategic opportunities this year, while executing our mid- to long-term strategy without disruption to meaningfully enhance corporate value.”
According to a regulatory filing made by Hanmi Pharmaceutical in South Korea on February 5, the Company recorded consolidated revenue of USD 1.15 billion (KRW 1.5475 trillion), operating profit of USD 191 million (KRW 257.8 billion), and net profit of USD 139 million (KRW 188.1 billion) last year.
Revenue increased 3.5% year-over-year, while operating profit and net profit grew 19.2% and 33.9%, respectively. Operating margin reached an industry-leading 16.7%, and the Company invested USD 170 million (KRW 229.0 billion) in R&D, equivalent to 14.8% of revenue.
Hanmi Pharmaceutical stated, “Strong growth in key products such as Rosuzet, expanded clinical supply shipments to partner MSD and growth in licensing-related income, along with the normalization of operations at Beijing Hanmi, contributed to the strong performance last year.” In the fourth quarter of 2025, revenue and operating profit were USD 321 million (KRW 433.0 billion) and USD 62 million (KRW 83.3 billion), respectively, representing increases of 23.1% and 173.4% year-over-year.
Hanmi Pharmaceutical achieved No. 1 in domestic outpatient prescription sales for eight consecutive years (based on [1]UBIST data) and generated USD 803 million (KRW 1.0836 trillion) in revenue from outpatient prescriptions alone last year. Rosuzet, a combination therapy for dyslipidemia, posted prescription sales of USD 169 million (KRW 227.9 billion), up 8.4% year-over-year, while the amlodipine+losartan-based antihypertensive combination franchise, the “Amosartan Family,” recorded USD 108 million (KRW 145.4 billion) in sales.
Beijing Hanmi Pharmaceutical, the Company’s local subsidiary in China, surpassed USD 296 million (KRW 400.0 billion) in annual revenue for the first time last year, making a solid contribution to Hanmi Pharmaceutical’s overall performance. With channel inventory normalization in China and seasonal peak demand driving higher sales of respiratory medicines such as Yianping and Itanjing, Beijing Hanmi posted full-year revenue of USD 298 million (KRW 402.4 billion), operating profit of USD 58 million (KRW 77.7 billion), and net profit of USD 50 million (KRW 67.4 billion). This marks the first time since its establishment in 1996 that Beijing Hanmi’s annual revenue has exceeded USD 296 million (KRW 400.0 billion).
Hanmi Fine Chemical, an affiliate specializing in active pharmaceutical ingredients (APIs), generated revenue of USD 68 million (KRW 91.3 billion) last year, and fourth-quarter revenue increased 36.8% year-over-year to USD 21 million (KRW 28.3 billion). Notably, in the fourth quarter, operating profit returned to profitability, supported by new order inflows in the CDMO business and expanded volumes from existing projects.
This year, Hanmi Pharmaceutical expects to enter a full-fledged high-growth trajectory, as momentum from innovative products and progress in global new drug development align to drive both scale expansion and profitability. Starting with Amoprel―the world’s first 1/3-dose triple antihypertensive―launched in the second half of last year, the Company plans to launch at least one “flagship product” annually with value potential of USD 7 million (KRW 10.0 billion) or more in annual sales.
In R&D, as a ‘new drug-focused pharmaceutical company,’ Hanmi is accelerating the development of globally innovative medicines through a differentiated strategy incorporating new modalities. This year, clinical results from key pipelines across oncology, obesity/metabolic disease, and rare diseases are expected to be presented sequentially at major global medical conferences.
In particular, the Company’s drug development achievements generated through the obesity program ‘H.O.P (Hanmi Obesity Pipeline)’ are becoming increasingly visible. Epeglenatide, the lead asset of the project, is approaching commercialization in the second half of this year, raising expectations that it could establish itself as a widely adopted obesity treatment.
In addition, the Company has set target commercialization timelines of 2030 and 2031, respectively, for its next-generation triple-agonist obesity therapy (LA-GLP/GIP/GCG, HM15275) and the world’s first muscle-increasing obesity therapy (LA-UCN2, HM17321), and is accelerating clinical development by concentrating company-wide capabilities.
Jae-hyun Park, CEO of Hanmi Pharmaceutical, said, “As Hanmi embarks on its next leap forward, we are moving decisively toward broader markets and diverse opportunities, supported by product competitiveness secured through proprietary technology,” adding, “We will continue to focus our full capabilities on delivering sustainable performance and further enhancing corporate value, thereby earning the trust and support of all stakeholders, including our shareholders.”
[1] UBIST is a Korean healthcare data company that provides prescription-based market data commonly used by pharmaceutical companies and analysts.